Article
CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Jun 2013
de Graan Anne-Joy M, Elens Laure, Sprowl Jason A, Sparreboom Alex, Friberg Lena E, van der Holt Bronno, de Raaf Pleun J, de Bruijn Peter, Engels Frederike K, Eskens Ferry A L M, Wiemer Erik A C, Verweij Jaap, Mathijssen Ron H J, van Schaik Ron H N
Abstract excerpt
PURPOSE: Paclitaxel is used for the treatment of several solid tumors and displays a high interindividual variation in exposure and toxicity. Neurotoxicity is one of the most prominent side effects of paclitaxel. This study explores potential predictive pharmacokinetic and pharmacogenetic determinants for the onset and severity of neurotoxicity. EXPERIMENTAL DESIGN: In an exploratory cohort of patients (n = 261)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.